Haloperidol Kinetics in Senile Dementia

  • M. Nishimoto
  • T. Itaya
  • Ko. Ohara
  • K. Miyasato
  • Ke. Ohara
Conference paper


The number of patients with dementie disease has increased and psychotic symptoms and behavioral disturbances with dementia are also observed.1 In these cases, antipsychotic drugs such as haloperidol has been widely used, the dosage generally based on a doctor’s clinical experience. Particularly in aged patients, individual deviation in pharmacokinetics becomes large and therapeutic dosage may often induce side effects such as the extrapyramidal syndrome. Thus, in the aged, it is especially important to establish an administration scheme on the basis of pharmacokinetic findings. Haloperidol is the most commonly prescribed antipsychotic drugs. Plasma concentration has been examined for all of the antipsychotic drugs, but haloperidol is considered the ideal agent for such studies because of the drug’s relatively simple metabolic pathway.2 Although, there have been many reports on the plasma concentration and clinical effects of haloperidol, those on effective plasma levels in aged patients are few. In the present study, we compared the plasma levels of haloperidol in the démentie patients above the age of 65 years who were given haloperidol due to psychotic symptoms such as delirium, hallucination, delusion and behavioral disturbances with those in schizophrenic patients under the age of 65.


Antipsychotic Drug Psychotic Symptom Behavioral Symptom Behavioral Disturbance Senile Dementia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Rabins PV, Mace NL, Lucas MJ (1982) The impact of dementia on the family. JAMA 248: 333–335PubMedCrossRefGoogle Scholar
  2. [2]
    Forsman A, Folsch G, Larsson M, Ohman R (1977) On the metabolism of haloperidol in man. Curr. Then Res. 21: 606–617Google Scholar
  3. [3]
    American Psychiatric Association. DSM-III: Diagnostic and Stastical Manual of Mental Disorders. 3rd. Washington, DC: APA, 1980Google Scholar
  4. [4]
    Korpi ER, Phelps BH, Granger H, Chang W-H, Linnolia M, Meek JL, Wyatt RJ (1983) Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clin Chem 29: 624–628PubMedGoogle Scholar
  5. [5]
    Tewfick GI, Jain VK, Harcup M (1970) Effectiveness of various tranquilizers in the management of senile restlessness. Gerontol Clin 12: 351–359CrossRefGoogle Scholar
  6. [6]
    Tsuang P, Lu LM, Stotsky BA (1971) Haloperidol versus thioridazine for hospitalized psychogeriatric patients: Double-blind study. J Am Geriatr Soc 19:593–597PubMedGoogle Scholar
  7. [7]
    Rada R, Kellner R (1976) Thiothixene in treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 24: 105–109PubMedGoogle Scholar
  8. [8]
    Cahn LA, Diesfeldt HFA (1973) The use of neuroleptics in the treatment of dementia in old age. Psych Neurol Neurochir 76: 411–420Google Scholar
  9. [9]
    Reifler BV, Larson E, Cox G (1982) Treatment results at a multispecialty clinic for the impaired elderly and their families. J Am Geriatr Soc 29: 579–582Google Scholar
  10. [10]
    Steele C, Lucas MJ, Tune L (1986) Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of Alzheimer’s type: Preliminary findings. J Clin Psychiatry 47:310–312PubMedGoogle Scholar
  11. [11]
    Putten TV, Marder SR, Mintz J, Poland RE (1988) Haloperidol plasma levels and clinical response: A therapeutic window relationship. Psychopharmacol Bull 24:172–175PubMedGoogle Scholar
  12. [12]
    Greenblatt DJ, Sellers EM, Shader RI (1982) Drug disposition in old age. New Engl J Med 306:1081–1088PubMedCrossRefGoogle Scholar
  13. [13]
    Aoba A, Yamaguchi N, Shido M (1986) Difference in the age effect on plasma neuroleptic levels between haloperidol and chlorpromazine in psychiatric patients. In: Clinical and Pharmacological Studies in Psychiatric Disorders. John Libbey and Company Ltd., London: 222–229Google Scholar

Copyright information

© Springer Japan 1992

Authors and Affiliations

  • M. Nishimoto
    • 1
  • T. Itaya
    • 1
  • Ko. Ohara
    • 1
  • K. Miyasato
    • 1
  • Ke. Ohara
    • 1
  1. 1.Department of Psychiatry and NeurologyHamamatsu University School of MedicineHamamatsuJapan

Personalised recommendations